Summary Alcobra Ltd (Alcobra) is a pharmaceutical company that develops and commercializes proprietary pharmaceutical products and novel treatments for CNS. The company offers non-stimulant products that are used in treatment of central nervous system disorders and cognitive dysfunctions.
It provides development and commercialization of its investigational new novel Phase III drug candidate, metadoxine extended release. Alcbra’s MDX acts as a monoamine-independent modulator of GABA transmission. The company conducts clinical studies and separate Phase IIb trials of MDX.
It also provides phase II studies and a phase III study of MDX in adults with ADHD. Alcobra is headquartered in Tel Aviv, Israel.
Alcobra Ltd (ADHD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
The kidney cancer therapeutics & diagnostics market will show a rapid growth due to the rising number of kidney cancer cases and increased R&D expenditure of the pharmaceutical companies. - According to the GLOBOCAN, the incidence of Kidney cancer is 4.5 per 100,000 in 2018, worldwide. The 5 major countries contributing to the global...
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis II - Pipeline Review, H1 2020, provides an overview of the Mucopolysaccharidosis II (Metabolic Disorders) pipeline landscape. Mucopolysaccharidosis...
214 pages •
By Asia Market Information & Development Company
• May 2020
China’s demand for Diabetes Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption...
Male Infertility Global Clinical Trials Review, H1, 2020 Summary This clinical trial report, “Male Infertility Global Clinical Trials Review, H1, 2020" provides an overview of Male Infertility Clinical trials scenario.This report provides top line data relating to the clinical trials on Male Infertility. Report...
The transdermal drug delivery system market was valued at US$ 6,063.85 million in 2019 and is projected to reach US$ 8,415.04 million by 2027; it is expected to grow at a CAGR of 4.3% during 2020-2027. The growth of the transdermal drug delivery system market is mainly attributed to factors such as the increasing prevalence of chronic diseases,...
319 pages •
By The Business Research Company
• Apr 2020
Anti-Asthmatics And COPD Drugs Global Market Opportunities And Strategies To 2030: COVID 19 Implications and Growth report provides the strategists, marketers and senior management with the critical information they need to assess the demand for anti-asthmatics and COPD drugs market which play a critical role in the treatment of patients with...
Radiodermatitis - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Radiodermatitis - Pipeline Review, H1 2020, provides an overview of the Radiodermatitis (Toxicology) pipeline landscape. Radiodermatitis is an inflammation of the skin caused...